Q1. Could you describe the roles where you were directly accountable for outcomes or major decisions, and the scale of operations, teams, or investments you were responsible for?

Let me introduce myself — Arindam Biswas, Owner of Zantus Lifesciences. I have worked with various pharmaceutical and nutrition companies over the past 2 decades across sales, marketing, business development, go-to-market, and commercial excellence. I have held multiple leadership roles at my previous assignments - Nestlé and Abbott Nutrition, launching new business verticals.
My responsibilities included go-to-market strategy, field force deployment, salesforce automation and excellence, capability building, and training interventions for the field force, making the team future-ready with digital initiatives, especially during the COVID period.
I also drove business analytics, linking insights to market trends and ensuring business compliance. My focus was on enhancing organizational productivity through various strategic levers and execution excellence, managing a team of 20 professionals.
Recently, I co-founded Zantus Life Sciences. Our mission is to address critical gaps in the Indian nutrition market with innovative, evidence-based products. For instance, we have partnered with a leading pharmaceutical company to launch a unique pediatric nutrition formula. Zantus has been instrumental in developing a low-carb, high-fiber meal-replacement solution called “ReduCarb” for diabetes, prediabetes, weight management, and PCOS. We also launched NutriLeap, which combines clinical nutrition with herbal ingredients - ashwagandha for better stamina, improved mood, and overall well-being.
As Founder, I have been directly accountable for strategy, product development, regulatory positioning, clinical investments, capital allocation, and go-to-market execution.

Q2. What is the one change in lifesciences today that most materially alters leadership decision-making, and why has it become decisive now rather than two years ago?

The decisive shift is the demand for evidence-backed differentiation.
Two years ago, speed to market mattered; today, clinical validation, regulatory defensibility, and scientific credibility determine success—specifically in nutrition and metabolic health.

Q3. Where are digital tools, AI, or advanced manufacturing creating the most meaningful operational impact in lifesciences today, and where do investments struggle to translate into real returns?

AI is creating real value in demand forecasting, clinical data analysis, and targeted consumer acquisition.
However, many digital investments fail when they chase visibility metrics rather than improving unit economics, conversion efficiency, or supply chain precision.

Q4. Where do regulatory, ESG, or quality-compliance requirements most meaningfully constrain growth or margins in lifesciences, and how are leading operators managing those trade-offs?

Regulatory governance and adherence to compliance are non-negotiable.
Regulatory scrutiny around claims and quality compliance directly impacts margins.
Leading players manage this by investing early in documentation, clinical studies, and clean-label positioning—turning compliance into a competitive advantage rather than a cost burden.

Q5. Which part of the lifesciences value chain feels most fragile today, and what early signals indicate stress before it turns into disruption?

Raw material sourcing and supply chain reliability are the two most fragile areas.
Early warning signs include wrong vendor selection, inconsistent quality lots & longer validation cycles—long before actual stockouts occur.

Q6. Which markets or segments appear most attractive in the data right now, yet require the most operational capability to scale successfully, and what makes them challenging?

Metabolic health and GLP-1 complementary nutrition look extremely attractive.
But scaling here requires:
•    Clinical substantiation
•    Responsible messaging
•    Physician education
•    Strong unit economics

Q7. If you were allocating capital in lifesciences today, what question would you ask management that most investors still overlook, and what kind of answer would raise concern for you?

“If your differentiation was audited by a regulator and a clinician tomorrow, would it survive?”
In nutrition, narrative scales faster than science.
But science sustains valuation. 
At Zantus, we are building for the second.